Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961237 | 1.00 | CYP2D6 (0.40) | CYP2D6CYP19A1CYP2C9CYP2C19KDM4E | |
| SCHEMBL2112054 | 0.82 | CYP2D6 (0.32) | CYP2D6CYP19A1CYP2C9CYP2C19KDM4E | |
| SCHEMBL29785697 | 0.73 | KDM4E (0.33) | KDM4EMAPTHPGD | |
| SCHEMBL28786363 | 0.73 | KDM4E (0.33) | KDM4EMAPTHPGD | |
| SCHEMBL29390052 | 0.73 | CYP1A2 (0.41) | CYP2D6CYP19A1CYP2C9CYP2C19KDM4E | |
| SCHEMBL28505 | 0.73 | CYP1A2 (0.41) | CYP2D6CYP19A1CYP2C9CYP2C19KDM4E | |
| SCHEMBL4037008 | 0.73 | CYP1A2 (0.41) | CYP2D6CYP19A1CYP2C9CYP2C19KDM4E | |
| SCHEMBL2416251 | 0.72 | — | — | |
| SCHEMBL1763340 | 0.72 | GABRP (0.34) | KDM4ERAB9ANPC1 | |
| SCHEMBL1417302 | 0.72 | CYP2D6 (0.42) | CYP2D6KDM4ETDP1L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745117-A1 | NOVEL INDENONE DERIVATIVE AND USE THEREOF | Amyloid Solution Inc. (KR) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132126-A1 | IMIDAZOLE DERIVATIVES | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | EIKONIZO THERAPEUTICS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260098026-A1 | M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | INCYTE CORP (US) | 2026-04-09 | — | — | US | disclosed |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-6054435-A | 6-O-substituted macrolides having antibacterial activity | ABBOTT LABORATORIES (US) | 2000-04-25 | — | — | US | disclosed |
| US-6046195-A | Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | disclosed |
| WO-2000010566-A1 | NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0623622-B1 | PROCESS FOR PRODUCING CEPHEM COMPOUND | OTSUKA KAGAKU KK (JP) | 1999-10-06 | — | — | EP | disclosed |
| EP-0937072-A1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A? $g(a)5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LTD. (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0929554-A1 | SPIRO-AZACYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998018792-A1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABAA α5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LIMITED (GB) | 1998-05-07 | — | — | WO | disclosed |
| WO-1998013369-A1 | SPIRO-AZACYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| US-5656754-A | REACTING AN ALLENYL-B-LACTAM COMPOUND WITH AN ORGANOTIN COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-08-12 | — | — | US | disclosed |
| EP-0623622-A1 | PROCESS FOR PRODUCING CEPHEM COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, MAPT, SLC6A6 | CYP2D6 266/4885CYP19A1 472/4885CYP2C9 473/4885 |
| US-20260132126-A1 | IMIDAZOLE DERIVATIVES | ADRA1A, ADRA1D, ADRB1 | CYP2D6 787/4885CYP19A1 1981/4885CYP2C9 1546/4885 |
| US-20260098026-A1 | M4 ACTIVATORS/MODULATORS AND USES THEREOF | CHRM1, CHRM2, CHRM4 | CYP2D6 268/4885CYP19A1 2503/4885CYP2C9 1309/4885 |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | CYP2D6 2689/4885CYP19A1 2273/4885CYP2C9 3684/4885 |
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | CNR1, CNR2, OPRM1 | CYP2D6 611/4885CYP19A1 1861/4885CYP2C9 515/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | CYP2D6 1293/4885CYP19A1 3875/4885CYP2C9 377/4885 |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | HDAC6, HDAC1, HDAC8 | CYP2D6 2410/4885CYP19A1 4433/4885CYP2C9 3810/4885 |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | JAK1, TYK2, JAK2 | CYP2D6 1054/4885CYP19A1 2919/4885CYP2C9 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.